RE: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update: Quantitative Risk Assessment and Controversial Issues

We have read with greatest interest the recent AAOMS′ Position Paper on Medication-Related Osteonecrosis of the Jaw (MRONJ) 1 Ruggiero S.L. Dodson T.B. Aghaloo T. Carlson E.R. Ward B.B. Kademani D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the Jaws—2022 update. J Oral Maxillofac Surg. 2022; 80: 920 Abstract Full Text Full Text PDF PubMed Scopus (38) Google Scholar regarding the quantitative risk assessment in patients affected by bone metastases from solid cancer or by multiple myeloma. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 UpdateJournal of Oral and Maxillofacial SurgeryVol. 80Issue 5PreviewStrategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaws (MRONJ) – formerly referred to as bisphosphonate-related osteonecrosis of the jaws (BRONJ)—were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007, 2009 and 2014. The position papers were developed by a committee appointed by the AAOMS Board of Trustees and comprising clinicians with extensive experience in caring for these patients, as well as clinical and basic science researchers. Full-Text PDF